The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.
Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN. · 2019
Read The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. by Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6591610.txt.
Introduction
Diekema and co-authors chart twenty years of bloodstream infection microbiology from the SENTRY surveillance program, writing in Antimicrobial Agents and Chemotherapy. The program collected 264,901 infection isolates from over 200 medical centers in 45 nations between 1997 and 2016, all identified and drug-tested at one central laboratory.
Two organisms dominate throughout: Staphylococcus aureus and Escherichia coli together caused over 40% of infections. Their balance shifted, though — E. coli's share climbed from about 19% to 24% while S. aureus slipped from about 23% to 19%, and Gram-negative bacteria gained ground overall. Pneumococcus faded to under 2%, and drug-resistant staph rose until the mid-2000s before retreating in every region. The tables break the patterns down by region, age and where infection began.
Catalog record
| CREATOR | Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program By Daniel J Diekema, Po-Ren Hsueh, Rodrigo E Mendes, Michael A Pfaller, Kenneth V Rolston, Helio S Sader, Ronald N Jones Published in: Antimicrobial Agents and Chemotherapy DOI: 10.1128/AAC.00355-19 ABSTRACT Bloodstream infection (BSI) organisms were consecutively collected from >200 medical centers in 45 nations between 1997 and 2016. Species identification and susceptibility testing followed Clinical and Laboratory Standards Institute broth microdilution methods at a central laboratory. KEYWORDS: antimicrobial resistance, bloodstream infection, surveillance INTRODUCTION Bloodstream infection (BSI) causes significant patient morbidity and mortality worldwide (1). Changing antimicrobial resistance (AMR) rates, pathogen distribution, demographics, and medical care delivery all may affect the epidemiology of BSI; therefore, continuously monitoring trends in the microbiology of BSI pathogens worldwide is very important. Examining microbiological trends can help inform diagnostic approaches, treatment strategies, and prevention programs. A major concern has been the emergence and global spread of multidrug-resistant (MDR) organisms, including oxacillin-resistant Staphylococcus aureus (ORSA), vancomycin-resistant Enterococcus spp. (VRE), and MDR Gram-negative bacilli (GNB) (including extended-spectrum-β-lactamase [ESBL] producers), carbapenem-resistant Enterobacteriaceae (CRE), and MDR nonfermenters such as Pseudomonas aeruginosa and Acinetobacter spp. Several studies have demonstrated the high mortality attributable to BSI due to these MDR organisms (2–5). The SENTRY Antimicrobial Surveillance Program was established in 1997 to monitor the predominant bacterial pathogens and the antimicrobial resistance patterns of organisms isolated from patients with various infection types, including BSI (6). We now report trends in organism distribution and AMR among BSI isolates submitted to the SENTRY Program during the first 20 years of the program (1997 to 2016). RESULTS Among the 264,901 BSI isolates collected, the most common pathogens overall were S. aureus and Escherichia coli (together accounting for over 40% of BSIs), followed by Klebsiella pneumoniae, P. aeruginosa, and Enterococcus faecalis (see Table 1). Notably, the number of E. coli isolates increased (from 18.7% in 1997 to 2000, to 24.0% in 2013 to 2016) whereas the number of S. aureus isolates declined (from 22.5% to 18.7%), as an overall proportion of all BSI. This change was accompanied by an increase in the proportion of GNB among the top 10 pathogens causing BSI (from 33.5% to 43.4% between the years 1997 to 2000 and the years 2013 to 2016). The proportion of Streptococcus pneumoniae isolates declined from 4.2% of all BSI in 1997 to 2000 to less than 2.0% of all BSI in 2009 to 2016. [Table: Rank order of pathogens causing bloodstream infection worldwide in the SENTRY Program by 4-year period] Pathogen frequency varied somewhat over time and by region, hospital-onset (HO) or community-onset (CO) status, and age (see Tables 1, 2, 3, and 4). However, S. aureus and E. coli remained predominant, with S. aureus representing a larger proportion of BSIs in North and Latin America (24.5% and 20.1% overall, respectively), while E. coli was predominant in Europe and the Asia-Pacific region (24.1% and 26.0% overall, respectively). Major decreases in the frequency of S. aureus detection occurred in Latin America (from 21.5% in 1997 to 2000 to 16.4% in 2013 to 2016) and the Asia-Pacific region (from 20.8% to 13.9%; Table 2). S. pneumoniae frequency decreased during the study period, especially in Latin America (from 4.0% in 1997 to 2000 to 0.4% in 2013 to 2016) and the Asia-Pacific region (from 4.6% to 0.9%). In contrast, E. coli and K. pneumoniae frequencies increased in all regions, with the greatest increases in Europe and the Asia-Pacific regions (Table 2). Acinetobacter spp. represented higher proportions of BSI in Latin America and the Asia-Pacific regions (4.4% and 3.2% overall, respectively) than elsewhere. [Table: Rank order and frequency of most common organisms causing bloodstream infections in the 1997-to-2000 and 2013-to-2016 time periods stratified by region] [Table: Rank order of pathogens causing bloodstream infection worldwide submitted to the SENTRY Program, 1997–2016, by age group] [Table: Rank order of pathogens causing BSI worldwide submitted to the SENTRY Program, 1997–2016, by community or hospital onset] While E. coli and S. aureus were the two most common causes of BSI in both HO-BSI and CO-BSI, they were much more predominant for CO-BSI (57.8% versus 31.3% for HO-BSI). HO-BSI was more often due to non-E. coli GNB (P. aeruginosa and Acinetobacter spp.; Table 4). The prevalence of ORSA increased until 2005 to 2008 and then declined in all regions and among HO-BSI and CO-BSI (Fig. 1). Of the 56,575 S. aureus BSI isolates tested against vancomycin, only 1 had a vancomycin MIC in the CLSI nonsusceptible category (8 mg/liter), and no trend toward an increase in the vancomycin MIC over time (“MIC creep”) was detected. The proportion of VRE (vancomycin MIC, >4 mg/liter) declined after 2012 and was 16.4% overall (see Fig. 2). Daptomycin resistance among S. aureus and enterococci remained rare (<0.1%). [Figure: Twenty-year trend in percent methicillin-resistant S. aureus (MRSA) among all S. aureus bloodstream infections, SENTRY, 1997 to 2016.] [Figure: Twenty-year trend in percent vancomycin-resistant enterococci (VRE) among Enterococcus sp. bloodstream infections, SENTRY, 1997 to 2016.] The frequency of MDR Enterobacteriaceae among all Enterobacteriaceae isolates increased from 6.2% in 1997 to 2000 to 15.8% in 2013 to 2016 and was highest among the HO-BSI isolates (Fig. 3). The frequency of MDR among Enterobacteriaceae varied by region, with the highest rates observed in Latin America (28.1%). ESBL-phenotype E. coli, ESBL-phenotype Klebsiella spp., and CRE phenotypes also increased over the surveillance period (Fig. 4). MDR rates were highest among the nonfermentative GNB (P. aeruginosa at 26.3% and Acinetobacter baumannii-Acinetobacter calcoaceticus complex at 70.6%); 48 isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus (0.9%) and 9 isolates of P. aeruginosa (<0.1%) were pan-drug resistant. Colistin was the only agent with predictable activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex (96.9% susceptible; Table 5). [Figure: Twenty-year trend in percent multidrug resistance (MDR) among Enterobacteriaceae bloodstream infection, by community-onset versus hospital-onset infection, SENTRY, 1997 to 2016.] [Figure: Twenty-year trend in percent extended-spectrum-β-lactamase (ESBL)-resistant and carbapenem-resistant Enterobacteriaceae (CRE) among selected Enterobacteriaceae, SENTRY, 1997 to 2016.] [Table: Activity of antimicrobial agents tested against Staphylococcus aureus, Enterobacteriaceae, and Acinetobacter baumannii-Acinetobacter calcoaceticus species complex submitted to the SENTRY Program, 1997–2016] The antimicrobial activity of selected agents against the 107,617 Enterobacteriaceae isolates is outlined in Table 5. Over 95% of these BSI pathogens were susceptible in vitro to amikacin, ceftazidime-avibactam, carbapenems, and tigecycline. DISCUSSION Many surveillance programs are designed to monitor trends in BSI. However, the scope of most programs is limited to specific patient populations, countries, or regions (5, 7–13) and the programs do not confirm the organism identification or susceptibility data at a reference laboratory. The SENTRY Program performs global surveillance, monitoring pathogens from consecutive BSI episodes and testing all isolates at the central reference laboratory (6). Collecting isolates from consecutive episodes allows inference of rates of prevalence at each site, providing the opportunity to examine large-scale trends. Major findings from the first 2 decades of SENTRY Program BSI surveillance include (i) the predominance of S. aureus and E. coli as BSI pathogens worldwide, (ii) the decline in the proportion of BSI due to important resistant Gram-positive pathogens (ORSA, VRE, daptomycin resistance among S. aureus and enterococci [DRE]) during the second decade of surveillance, and (iii) the ongoing increase in the detection of GNB and in MDR-GNB as a proportion of